www.thelancet.com/infection Vol 9 July 2009
7 Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD,
Deeks SG. Long-term consequences of the delay between virologic
failure of highly active antiretroviral therapy and regimen
modiﬁ cation. AIDS 2008; 22: 2097–106.
8 Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.
Stavudine, lamivudine and nevirapine combination therapy for
treatment of HIV infection and AIDS in adults.
Cochrane Database Syst Rev 2006; 2: CD004535.
9 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF.
Improving the quality of reports of meta-analyses of randomised
controlled trials: the QUOROM statement. Lancet 1999;
10 US Food and Drug Administration. Drugs used in the treatment of
HIV infection. http://www.fda.gov/oashi/aids/virals.html
(accessed May 19, 2009).
11 The UK Collaborative HIV Cohort Steering Committee. The
creation of a large UK-based multicentre cohort of HIV-infected
individuals: the UK collaborative HIV cohort (UK CHIC) study.
HIV Medicine 2004; 5: 115–24.
12 Ledergerber B, Egger M, Opravil M, et al. Clinical progression and
virological failure on highly active antiretroviral therapy in HIV-1
patients: a prospective cohort study. Lancet 1999; 353: 863–68.
13 Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-
resistance mutations in a large antiretroviral-naive cohort initiating
triple antiretroviral therapy. J Infect Dis 2005; 191: 339–47.
14 Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active
antiretroviral therapy in a rural district of Malawi: an eﬀ ectiveness
assessment. Lancet 2006; 367: 1335–42.
15 DART trial team. Twenty-four-week safety and tolerability of
nevirapine vs abacavir in combination with zidovudine/lamivudine
as ﬁ rst-line antiretroviral therapy: a randomized double-blind trial
(NORA). Trop Med Int Health 2008; 13: 6–16.
16 Ndembi N, Pillay D, Goodall R, et al. Diﬀ erences in the dynamics of
viral rebound and evolution of resistance between CBV/NVP and
CBV/ABC uncovered in the absence of viral load monitoring in real
time: NORA substudy of the DART trial. 15th conference on
retroviruses and opportunistic infections; Boston, USA;
Feb 3–6, 2008. Abstract 889.
17 Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-
term viral failure among Ugandan children and adults treated with
antiretroviral therapy. J Acquir Immune Deﬁ c Syndr 2007; 46: 187–93.
18 Charles M, Noel F, Leger P, et al. Survival, plasma HIV-1 RNA
concentrations and drug resistance in HIV-1-infected Haitian
adolescents and young adults on antiretrovirals.
Bull World Health Organ 2008; 86: 970–77.
19 Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B,
Chumpathat N, Chantratita W. Options for a second-line
antiretroviral regimen for HIV type 1-infected patients whose initial
regimen of a ﬁ xed-dose combination of stavudine, lamivudine, and
nevirapine fails. Clin Infect Dis 2007; 44: 447–52.
20 Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug
resistance after failure of a ﬁ rst highly active antiretroviral therapy
regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;
21 Laurent C, Kouanfack C, Koulla-Shiro S, et al. Eﬀ ectiveness and
safety of a generic ﬁ xed-dose combination of nevirapine, stavudine,
and lamivudine in HIV-1-infected adults in Cameroon: open-label
multicentre trial. Lancet 2004; 364: 29–34.
22 Phillips AN, Dunn D, Sabin C, et al. Long term probability of
detection of HIV-1 drug resistance after starting antiretroviral
therapy in routine clinical practice. AIDS 2005; 19: 487–94.
23 von Wyl V, Yerly S, Böni J, et al. Emergence of HIV-1 drug
resistance in previously untreated patients initiating combination
antiretroviral treatment: a comparison of diﬀ
erent regimen types.
Arch Intern Med 2007; 167: 1782–90.
Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ.
Performance of a World Health Organization ﬁ rst-line regimen
(stavudine/lamivudine/nevirapine) in antiretroviral-naïve
individuals in a Western setting. HIV Med 2007; 8: 267–70.
25 Mocroft A, Kirk O, Aldins P, et al. Loss to follow-up in an
international, multicentre observational study. HIV Med 2008;
26 Armitage P, Berry G. Statistical methods in medical research,
3rd edn. Oxford: Blackwell Scientiﬁ c Publications, 1994.
27 van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of
ﬁ rst-line antiretroviral therapy with regimens including nevirapine,
efavirenz, or both drugs, plus stavudine and lamivudine: a
randomised open-label trial, the 2NN Study. Lancet 2004;
28 Hall D, van Leth F, Schere J, et al. Genotypic analysis of reverse
transcriptase in treatment-naïve HIV-1 patients treated with
lamivudine, stavudine and nevirapine and/or efavirenz.
11th conference on retroviruses and opportunistic infections;
San Francisco, USA; Feb 8–11, 2004. Abstract 694.
29 Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical
trial comparing nelﬁ navir or nevirapine associated to zidovudine/
lamivudine in HIV-infected naive patients (the Combine Study).
Antivir Ther 2002; 7: 81–90.
30 Ferrer E, Podzamczer D, Arnedo M, et al. Genotype and phenotype
at baseline and at failure in human immunodeﬁ ciency virus-
infected antiretroviral-naive patients in a randomized trial
comparing zidovudine and lamivudine plus nelﬁ navir or
nevirapine. J Infect Dis 2003; 187: 687–90.
31 Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine,
and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV.
N Engl J Med 2006; 354: 251–60.
32 Gallant JE, Staszewski S, Pozniak AL, et al. Eﬃ cacy and safety of
tenofovir DF vs stavudine in combination therapy in antiretroviral-
naive patients: a 3-year randomized trial. JAMA 2004; 292: 191–201.
33 DeJesus E, Herrera G, Teoﬁ lo E, et al. Abacavir versus zidovudine
combined with lamivudine and efavirenz, for the treatment of
antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004;
34 DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily
lamivudine, in combination with zidovudine and efavirenz, for the
treatment of antiretroviral-naive adults with HIV infection:
a randomized equivalence trial. Clin Infect Dis 2004; 39: 411–18.
35 Vavro C, McCarty D, Shortino D, Hetherington S. Genotypic
analysis of HIV-1 from subjects experiencing virologic breakthrough
while taking 3TC QD vs 3TC BID, EFV and ZDV. 42nd interscience
conference on antimicrobial agents and chemotherapy; San Diego,
California; Sept 27–30, 2002. Abstract H-2052.
36 Cameron W, da Silva B, Arribas J,
et al. A two-year randomized
controlled clinical trial in antiretroviral-naïve subjects using
lopinavir/ritonavir (LPV/r) monotherapy after initial induction
treatment compared to an efavirenz (EFV) 3-drug regimen (Study
M03-613). 16th international AIDS conference; Toronto, Canada;
Aug 13–18, 2006. Abstract THLB0201.
37 Gupta RK, Hill A, Sawyer AW, Pillay D. Emergence of drug
resistance in HIV-1 infected patients after ﬁ rst-line highly active
antiretroviral therapy (HAART): a systematic review of clinical
trials. Clin Infect Dis 2008; 47: 712–22.
38 Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analogue
mutation proﬁ les: factors associated with acquiring speciﬁ c proﬁ les
and their impact on the virological response to therapy. Antivir Ther
2005; 10: 791–802.
39 Hoﬀ mann C, Charalambous S, Ledwaba J, et al. The rate of
developing ART resistance during HIV viraemia on HAART in
South Africa. 16th conference on retroviruses and opportunistic
infections; Montreal, Canada; Feb 8–11, 2009. Abstract 656.
40 Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring
of patients on antiretroviral therapy in resource-limited settings
with viral load, CD4 cell count, or clinical observation alone:
a computer simulation model. Lancet 2008; 371: 1443–51.
41 Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R,
Hoepelman AI. Rapid accumulation of nonnucleoside reverse
transcriptase inhibitor-associated resistance: evidence of
transmitted resistance in rural South Africa. AIDS 2008;
42 Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, et al.
Antiretroviral drug resistance among antiretroviral-naïve persons
with recent HIV infection in Thailand. HIV Med 2008; 9: 322–25.
43 Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for
resource-limited settings. PLoS Med 2006; 3: e417.